Computational Repurposing of FDA-Approved Drugs as Candidate MMP2 Inhibitors with Putative MMP3 Cross-Activity.

Tabrecta (capmatinib) - Novartis

Stivarga (regorafenib) - Bayer

http://www.ncbi.nlm.nih.gov/pubmed/42737654

Driss Cherqaoui; Francesca Bianchini; Ismail Hdoufane; Mehdi Oubahmane; Nouhaila Ait Lahcen; Saad Zekri; Wissal Liman

Sep 16, 2026